HBT Labs develops complex injectable medicines. We are a specialty pharmaceutical company focused on high barrier, parenteral generic drugs with complex chemistry and manufacturing processes. Our pipeline of drugs includes generic and 505(b)(2) products that target various treatment indications including cancer and CNS disorders. HBT has developed proprietary processes and technologies to produce complex drugs across multiple delivery platforms, including liposomes, nanoparticles, emulsions, and long-acting injectable suspensions. HBT’s goal is to provide lower-cost treatment options to patients worldwide.

Located in Brea, California, HBT operates a 24,000 square-foot cGMP facility that has been inspected by the US Food and Drug Administration and approved by the State of California for the manufacture of drugs. HBT also occupies a 20,000 square-foot facility for its research and development operations, administrative functions, and warehouse space.
Our mission is to develop and deliver cost-effective, high-quality therapeutics for patients in critical need.
HBT’s Quality Commitment
HBT provides patients with safe and effective drug products that meet our health care professionals’ and customers’ needs. We are committed to complying with regulatory requirements while driving continuous improvement of our HBT Compliance Management System to maintain its effectiveness. HBT senior management and employees understand their roles and responsibilities, and how they support the quality of our products and services.